London--(Marketwire - May 20, 2008) -

Curidium Medica plc ("Curidium" or the "Company")


London, UK, 20 May 2008, Curidium Medica plc, (LSE: CUR) the
personalized medicine company focused on bringing the right drug to the
right patient, today announced that Dr. Anne Bruinvels, Founder and
Chief Scientific Officer, will be presenting at the PharmaIQ's
Personalised Medicine 2008 in London on Thursday 22nd May at 14.00
local time at Cafe Royal, London.

Dr. Bruinvels will give a presentation entitled "Companion Diagnostics
and Targeted Medicines", and will be discussing PsychINDxTM, Curidium's
blood diagnostic tool to sub-classify the schizophrenia and bipolar
disorder patient population into different subgroups which may be
applied to stratify and optimize clinical trials of new antipsychotic
drug treatments.

Dr. Smita Price, Director of Psychiatry Research, will be presenting
at the EPIC Biotech conference in London on Thursday 22nd May at 14.10
local time at the Cumberland Hotel, London. Dr. Price will present an
overview of Curidium's latest developments.


For further information, please contact:

Anne T. Bruinvels, PhD +44 (0)20 7383 5345

Founder & CSO, Curidium Medica plc

Rob Smith +44 (0)20 7383 5345

Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0)20 7600 1658

JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113

Financial Dynamics

Notes to Editors

Curidium Medica plc

Curidium is a personalized medicine company identifying targeted
medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has
resulted in the identification of a blood diagnostic test, PsychINDxTM,
which classifies patients with schizophrenia/bipolar disorder into four
subgroups. PsychINDxTM may have the potential to improve the treatment
of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient
populations consist of mixed subgroups. Through the use of its
proprietary analysis tool, Homomatrix®, Curidium aims to reveal
different patient subgroups characterized by distinct underlying
disease mechanisms potentially leading to the identification of:

1.  Diagnostics for better identification and treatment within
heterogeneous disease populations.

2.  Improved therapies identified through novel drug targets.

3.  Personalized medicines using companion diagnostics and targeted

Curidium aims to continue to use this approach to improve patient
treatments in a variety of therapeutic areas. Further information on
Curidium can be found at the Company's website:

Curidium Medica plc © 2001-2008. All rights reserved.

Studio 10, Tiger House, London WC1H 9BY, United Kingdom.

Email: Tel.: +44 (0)20 7383 5345,
Fax: +44 (0)20 7383 2973

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information: Contacts: RNS Customer Services 0044-207797-4400